Expression changes of miR-582-5p and Rab27a in non-small cell lung cancer tissues and their relationship with clinicopathological parameters
GUO Yi1,2 GUO Wei2 WANG Yanhong3
1.School of Basic Medicine, Shanxi Medical University, Shanxi Province, Taiyuan 030003, China;
2.the Second Department of Respiratory, Shanxi Provincial Cancer Hospital, Shanxi Province, Taiyuan 030003, China;
3.Department of Microbiology and Immunology, Shanxi Medical University, Shanxi Province, Taiyuan 030003, China
Abstract：Objective To investigate the expression of miR-582-5p and RAS oncogene family Rab27a in non-small cell lung cancer (NSCLC) tissues and their relationship with clinicopathological parameters. Methods The expression of miR-582-5p and Rab27a levels in 120 NSCLC tissues and adjacent tissues were detected by real-time quantitative polymerase chain reaction (qRT-PCR). Rab27a protein expression level in tissues were detected by Western blot. The expressions differences of miR-582-5p and Rab27a and their relationships with clinicopathological features were analyzed statistically. Results Compared with adjacent tissues, the expression level of miR-582-5p was lower than that in NSCLC tissues, while the expression of Rab27a was higher (all P ＜ 0.05). Compared with TNM stage Ⅰ-Ⅱ cancer tissue without lymph node metastasis, the expression level of miR-582-5p in TNM stage Ⅲ-Ⅳ cancer tissue with lymph node metastasis was lower, while the expression level of Rab27a was higher (all P ＜ 0.05). There was a negative correlation between miR-582-5p and Rab27a expression levels in cancer tissues (r = -0.633，P = 0.000). Conclusion The expression level of miR-582-5p is decreased and the expression level of Rab27a is increased in NSCLC tissues, which may be new molecular markers for diagnosis and treatment of NSCLC.
郭毅1,2 郭伟2 王艳红3. 非小细胞肺癌组织中miR-582-5p、Rab27a的表达变化及与临床病理参数的关系[J]. 中国医药导报, 2020, 17(35): 108-111.
GUO Yi1,2 GUO Wei2 WANG Yanhong3. Expression changes of miR-582-5p and Rab27a in non-small cell lung cancer tissues and their relationship with clinicopathological parameters. 中国医药导报, 2020, 17(35): 108-111.
[1] Mao Y，Yang D，He J，et al. Epidemiology of Lung Cancer [J]. Surg Oncol Clin NAm，2016，25（3）：439-445.
[2] Nasim F，Sabath BF，Eapen GA. Lung Cancer [J]. Med Clin North Am，2019，103（3）：463-473.
[3] Zhang L，Liao Y，Tang L. MicroRNA-34 family：a potential tumor suppressor and therapeutic candidate in cancer [J]. J Exp Clin Cancer Res，2019，38（1）：1-13.
[4] Huang S，Zou C，Tang Y，et al. miR-582-3p and miR-582-5p Suppress Prostate Cancer Metastasis to Bone by Repressing TGF-βSignaling [J]. Mol Ther Nucleic Acids，2019，16：91-104.
[5] 陈承，黄静，耿旭洋，等.shRNA干扰长链非编码RNA UCA1对乳腺癌移植瘤模型肿瘤生长的抑制作用[J].武汉大学学报：医学版，2019，40（4）：534-539.
[6] Liu J，Gong X，Zhu X，et al. Rab27A overexpression promotes bladder cancer proliferation and chemoresistance through regulation of NF-κB signaling [J]. Oncotarget，2017，8（43）：75272.
[7] Li J，Jin Q，Huang F，et al. Effects of Rab27A and Rab27B on Invasion，Proliferation，Apoptosis，and Chemoresistance in Human Pancreatic Cancer Cells [J]. Pancreas，2017，46（9）：1173-1179.
[8] Rami-Porta R，Bolejack V，Giroux DJ，et al. The IASLC lung cancer staging project：the new database to inform the eighth edition of the TNM classification of lung cancer [J]. J Thorac Oncol，2014，9（11）：1618-1624.
[9] Torre LA，Bray F，Siegel RL，et al. Global cancer statistics，2012 [J]. CA Cancer J Clin，2015，65（2）：87-108.
[10] Watanabe SI，Nakagawa K，Suzuki K，et al. Lung Cancer Surgical Study Group（LCSSG）of the Japan Clinical Oncology Group（JCOG）. Neoadjuvant and adjuvant therapy for Stage Ⅲ non-small cell lung cancer [J]. Jpn J Clin Oncol，2017，47（12）：1112-1118.
[11] Wang JK，Wang Z，Li G. MicroRNA-125 in immunity and cancer [J]. Cancer Lett，2019，454（10）：134-145.
[12] Wang J，Su Z，Lu S，et al. LncRNA HOXA-AS2 and its molecular mechanisms in human cancer [J]. Clin Chim Acta，2018，485（5）：229-233.
[13] Zhang HD，Jiang LH，Sun DW，et al. CircRNA：a novel type of biomarker for cancer [J]. Breast Cancer，2018，25（1）：1-7.
[14] Yonemori K，Kurahara H，Maemura K，et al. MicroRNA in pancreatic cancer [J]. J Hum Genet，2017，62（1）：33-40.
[15] 黄耀孟，吴珺，李秉慧.miRNA在乳腺癌诊断、预后和预测中的应用[J].河北医科大学学报，2018，39（9）：1100-1106.
[16] 李安妮，鲁明骞.microRNA在甲状腺癌中的研究进展[J].临床耳鼻咽喉头颈外科杂志，2018，32（5）：397-400.
[17] Wu J，Li W，Ning J，et al. Long noncoding RNA UCA1 targets miR-582-5p and contributes to the progression and drug resistance of bladder cancer cells through ATG7-mediated autophagy inhibition [J]. Onco Targets Ther，2019，12（2）：495-508.
[18] Wang LL，Zhang M. miR-582-5p is a potential prognostic marker in human non-small cell lung cancer and functions as a tumor suppressor by targeting MAP3K2 [J]. Eur Rev Med Pharmacol Sci，2018，22（22）：7760-7767.
[19] Guo D，Lui GYL，Lai SL，et al. RAB27A promotes melanoma cell invasion and metastasis via regulation of pro-invasive exosomes [J]. Int J Cancer，2019，144（12）：3070-3085.
[20] Koh HM，Song DH. Prognostic role of Rab27A and Rab27B expression in patients with non-small cell lung carcinoma [J]. Thorac Cancer，2019，10（2）：143-149.
[21] Zhang X，Zhang Y，Yang J，et al. Upregulation of miR-582-5p inhibits cell proliferation，cell cycle progression and invasion by targeting Rab27a in human colorectal carcinoma [J]. Cancer Gene Ther，2015，22（10）：475-480.
[22] Tang L，Yin Y，Liu J，et al. MiR-124 Attenuates Osteoclastogenic Differentiation of Bone Marrow Monocytes Via Targeting Rab27a [J]. Cell Physiol Biochem，2017， 43（4）：1663-1672.
[23] An HJ，Song DH，Koh HM，et al. RAB27A is an independent prognostic factor in clear cell renal cell carcinoma [J]. Biomark Med，2019，13（4）：239-247.
[24] Guo D，Lui GYL，Lai SL，et al. RAB27A promotes melanoma cell invasion and metastasis via regulation of pro-invasive exosomes [J]. Int J Cancer，2019，144（12）：3070-3085.
[25] 叶璐，母丹，杨莉，等.miR-582-5p靶向抑制Rab27a对肺癌细胞生物学行为的影响[J].临床肿瘤学杂志，2019， 24（2）：12-17.
2020, Vol. 17 
京公网安备 11010502046598号